Abstract 394P
Background
Advanced small cell lung cancer patients have very poor outcome, with a median overall survival (OS) of less than 1 year. We conducted this phase II clinical trial to evaluate the efficacy and safety of apatinib plus etoposide capsules in the third-line or further-line treatment of patients with extensive stage small cell lung cancer.
Methods
Patients with extensive stage small cell lung cancer who failed ≥ 2 lines of therapy were recruited from 11 hospital across China. All participants should have an Eastern Cooperative Oncology Group performance status of 0 to 2, at least one evaluable lesion according to response evaluation criteria in solid tumor (RESCIST 1.1). Participants received apatinib (250mg orally every day) and etoposide capsules (50mg orally from day 1 to 21, every 4 weeks) until disease progression, death or intolerable toxicity. The primary endpoint was progression-free survival (PFS). The secondary endpoint was overall survival (OS) and safety.
Results
Totally 52 patients with a median age of 60.5 (range, 30-77) years, including 40 men (77.0%) were enrolled in our study from December 2017 to August 2019. By the end of December 2019, 45 patients progressed and 36 died. Among 52 evaluable patients, 34 patients showed a stable disease, 11 patients achieved a partial response, showing an objective response rate (ORR) of 21.2% and disease control rate (DCR) of 86.5%. The median follow-up duration was 6.6 months. The median PFS was 3.3 months (95% CI, 2.56-4.05), and median OS was 4.5 months (95% CI, 3.50-4.90). 1-year survival rate was 11.54%. Major adverse events (AEs) included leukopenia (30.77%), anemia (25%), and fatigue (19.23%). No grade 3 or more AEs were reported.
Conclusions
Apatinib plus etoposide capsules showed reasonable efficacy and toxicity among extensive stage small cell lung cancer patients in third-line or above setting. Further exploration of apatinib in phase Ⅲ trials is warranted.
Clinical trial identification
NCT03389087.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Jiangsu Hengrui Pharmaceutical Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Textbook outcome as a measure of surgical quality assessment and prognosis in gastric neuroendocrine carcinoma: A large multicenter sample analysis
Presenter: You-Xin Gao
Session: e-Poster Display Session
184P - Development and external validation of a nomogram to predict recurrence-free survival after R0 resection for stage II/III gastric adenocarcinoma: An international multicenter study
Presenter: Bin-Bin Xu
Session: e-Poster Display Session
185P - Effect of sarcopenia on short- and long-term outcomes of patients with gastric neuroendocrine tumour after radical surgery: Results from a large, two-institutional series
Presenter: Ling-Qian Wang
Session: e-Poster Display Session
186P - Characterization of the gastroenteropancreatic neuroendocrine tumour patient journey
Presenter: George Fisher Jr
Session: e-Poster Display Session
187P - More is not always better: A multicenter study in lymphadenectomy during gastrectomy for gastric neuroendocrine carcinoma
Presenter: Qi-Yue Chen
Session: e-Poster Display Session
188P - The impact of sarcopenia on chemotherapy toxicity and survival rate among pancreatic cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Billy Susanto
Session: e-Poster Display Session
189P - Prognostic value of inflammation-based score for patients treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP)
Presenter: Takahiro Yamamura
Session: e-Poster Display Session
190P - Outcomes from the Asian region of the phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for patients (pts) with resected pancreatic cancer (PC)
Presenter: Joon Oh Park
Session: e-Poster Display Session
191P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study
Presenter: Andrew Dean
Session: e-Poster Display Session
192P - A multicenter crossover analysis of first and second-line FOLFIRINOX or gemcitabine plus nab-paclitaxel administered to pancreatic cancer patients: Results from the NAPOLEON study
Presenter: Kenta Nio
Session: e-Poster Display Session